Joint replacements are the #1 expenditure of Medicare. The process of approving these medical devices is flawed according to the Institute of Medicine. It is time for patients' voices to be heard as stakeholders and for public support for increased medical device industry accountability and heightened protections for patients. Post-market registry. Product warranty. Patient/consumer stakeholder equity. Rescind industry pre-emptions/entitlements. All clinical trials must report all data.
Please share what you have learned!
Twitter: @JjrkCh

Wednesday, July 11, 2012

Selling Sickness 2013 - People Before Profits

February 20-22, 2012 at the Hyatt Regency on Capitol Hill, Washington, DC
 2006 Inaugural Congress on Disease Mongering in Australia  marked a watershed in networking among health care reformers and drug industry critics.
 2010 Selling Sickness conference in Amsterdam expanded the network and updated the work.
Selling Sickness 2013 will bring together academic scholars, healthcare reformers, consumer advocates and progressive health journalists to examine the global tide of disease mongering.
Conference will include topics pertaining to disease-mongering such as: misleading marketing; ethics in professional education; journalistic standards; social media; over-treatment; new models for drug development and testing; whistleblowers; new conflict of interest areas; health screening policies; impact on public health and pocketbook.
The conference is designed to encourage audience participation and increase collaboration among the conference attendees.
Kim Witczak 

Kim Witczak became involved in pharmaceutical drug safety issues after the death of her husband, Tim “Woody” Witczak in 2003 as a result of an undisclosed drug side effect. She has taken her personal experience and turned it into advocacy/public awareness campaign on drug safety which included the SSRI/suicide risk (which resulted in black box warnings being added to antidepressants), DTC advertising, undue Pharma influence, COI, PDUFA, and FDA reform. Kim has testified before US Senate on PDUFA/FDA reform as well as numerous FDA Advisory Committees. In 2008 she was appointed to the FDA’s Psychopharmacologic Drugs Advisory Committee as a Patient Representative. In 2004, Kim launched in memory of Woody’s life and death as a resource for others that live every day with the consequences of a flawed drug safety system.

No comments:

Post a Comment